Consolidated balance sheet
(in CHF 1 000)
|
|
|
Notes |
|
30.06.2021 |
|
31.12.2020 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
3 174 |
|
6 816 |
|
Receivables from brokers |
|
|
|
4 457 |
|
1 521 |
|
Securities |
|
4 |
|
4 349 265 |
|
3 954 659 |
|
Other assets |
|
|
|
174 |
|
139 |
|
|
|
|
|
4 357 070 |
|
3 963 135 |
|
Total assets |
|
|
|
4 357 070 |
|
3 963 135 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
5 |
|
300 000 |
|
63 000 |
|
Payables to brokers |
|
|
|
4 155 |
|
6 576 |
|
Other short-term liabilities |
|
|
|
5 736 |
|
5 709 |
|
Tax liabilities |
|
|
|
179 |
|
303 |
|
|
|
|
|
310 070 |
|
75 588 |
|
Total liabilities |
|
|
|
310 070 |
|
75 588 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
6 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
6 |
|
– |
|
(8 241) |
|
Retained earnings |
|
|
|
4 035 920 |
|
3 884 708 |
|
|
|
|
|
4 047 000 |
|
3 887 547 |
|
Total liabilities and shareholders' equity |
|
|
|
4 357 070 |
|
3 963 135 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
73.05 |
|
70.30 |
The notes are an integral part of the condensed consolidated interim financial statements.
The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on July 20, 2021.